Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Citius Pharmaceuticals (CTXR) Stock Price

Media stories about Citius Pharmaceuticals (NASDAQ:CTXR) have been trending somewhat positive on Thursday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Citius Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.4467953604312 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Citius Pharmaceuticals traded up $0.07, hitting $2.73, on Thursday, Marketbeat reports. 1,825 shares of the company traded hands, compared to its average volume of 31,635. Citius Pharmaceuticals has a 52 week low of $2.25 and a 52 week high of $6.60.

Separately, HC Wainwright began coverage on shares of Citius Pharmaceuticals in a research report on Wednesday, May 23rd. They set a “buy” rating and a $11.00 price objective on the stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido product, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply